• Patients were analyzed according to body weight (≤60, >60 to <100, ≥100 to <120, and ≥120 kg) and BMI categories (≤25, >25 to 30, >30 to 35, >35 to 40, and >40 kg/m2)
  • Primary efficacy outcome: Composite of recurrent symptomatic VTE or VTE-related death
  • Primary safety outcome: ISTH-defined major bleeding
  • Secondary safety outcome: Composite of major and CRNM bleeding
  • A population PK analysis was conducted to characterize apixaban exposure in VTE-treated patients